CNS Year in Review: Going Digital
Health Advances
APRIL 6, 2023
Many of these technologies are still cultivating evidence needed for use in widespread clinical practice. However, FDA’s regulatory guidance for digital health products has matured and made the path to market clearer. Thus, CNS-focused biopharmas should carefully consider digital biomarkers as they chart development paths.
52 
Let's personalize your content